Is the price fair?
What SEPN's price assumes
Septerna, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 14.9× revenue.
14.9
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 6.6%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +2.1%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
- Price / book
- 2.84
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 2.84
- EV / EBIToperating margin −77%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $107M
- Market capitalisation
- $1.63B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.